L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

Felix Kf Kommoss, Anthony Karnezis, Friedrich Kommoss, Aline Talhouk, Florin Andrei Taran, Annette Staebler, C. Blake Gilks, David G. Huntsman, Bernhard Krämer, Sara Y. Brucker, Jessica N. McAlpine, Stefan Kommoss

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort. Methods: ProMisE (POLE; MMR-D; p53 wt/NSMP; p53 abn) classification results from a cohort of 452 EC were available for analysis. L1CAM expression was studied by immunohistochemistry on whole slides. Correlations between clinicopathological data and survival were calculated. Results: Expression of L1CAM was most frequent in p53 abnormal tumours (80%). L1CAM status was predictive of worse outcome among tumours with no specific molecular profile (p53 wt/NSMP) (p < 0.0001). Among p53 wt/NSMP EC, L1CAM remained a significant prognosticator for disease-specific survival after multivariate analysis (p = 0.035). Conclusion: L1CAM status was able to significantly stratify risk among tumours of the large p53 wt/NSMP ProMisE subgroup of EC. Furthermore, our study confirms a highly significant correlation between mutation-type p53 immunostaining and abnormal L1CAM expression in EC.

Original languageEnglish (US)
JournalBritish Journal of Cancer
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Neural Cell Adhesion Molecule L1
Endometrial Neoplasms
Neoplasms
Survival
Multivariate Analysis
Immunohistochemistry
Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. / Kommoss, Felix Kf; Karnezis, Anthony; Kommoss, Friedrich; Talhouk, Aline; Taran, Florin Andrei; Staebler, Annette; Gilks, C. Blake; Huntsman, David G.; Krämer, Bernhard; Brucker, Sara Y.; McAlpine, Jessica N.; Kommoss, Stefan.

In: British Journal of Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Kommoss, FK, Karnezis, A, Kommoss, F, Talhouk, A, Taran, FA, Staebler, A, Gilks, CB, Huntsman, DG, Krämer, B, Brucker, SY, McAlpine, JN & Kommoss, S 2018, 'L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile', British Journal of Cancer. https://doi.org/10.1038/s41416-018-0187-6
Kommoss, Felix Kf ; Karnezis, Anthony ; Kommoss, Friedrich ; Talhouk, Aline ; Taran, Florin Andrei ; Staebler, Annette ; Gilks, C. Blake ; Huntsman, David G. ; Krämer, Bernhard ; Brucker, Sara Y. ; McAlpine, Jessica N. ; Kommoss, Stefan. / L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. In: British Journal of Cancer. 2018.
@article{1ebcc730977a4cddb33777fd9ae78cc7,
title = "L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile",
abstract = "Background: The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort. Methods: ProMisE (POLE; MMR-D; p53 wt/NSMP; p53 abn) classification results from a cohort of 452 EC were available for analysis. L1CAM expression was studied by immunohistochemistry on whole slides. Correlations between clinicopathological data and survival were calculated. Results: Expression of L1CAM was most frequent in p53 abnormal tumours (80{\%}). L1CAM status was predictive of worse outcome among tumours with no specific molecular profile (p53 wt/NSMP) (p < 0.0001). Among p53 wt/NSMP EC, L1CAM remained a significant prognosticator for disease-specific survival after multivariate analysis (p = 0.035). Conclusion: L1CAM status was able to significantly stratify risk among tumours of the large p53 wt/NSMP ProMisE subgroup of EC. Furthermore, our study confirms a highly significant correlation between mutation-type p53 immunostaining and abnormal L1CAM expression in EC.",
author = "Kommoss, {Felix Kf} and Anthony Karnezis and Friedrich Kommoss and Aline Talhouk and Taran, {Florin Andrei} and Annette Staebler and Gilks, {C. Blake} and Huntsman, {David G.} and Bernhard Kr{\"a}mer and Brucker, {Sara Y.} and McAlpine, {Jessica N.} and Stefan Kommoss",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41416-018-0187-6",
language = "English (US)",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

AU - Kommoss, Felix Kf

AU - Karnezis, Anthony

AU - Kommoss, Friedrich

AU - Talhouk, Aline

AU - Taran, Florin Andrei

AU - Staebler, Annette

AU - Gilks, C. Blake

AU - Huntsman, David G.

AU - Krämer, Bernhard

AU - Brucker, Sara Y.

AU - McAlpine, Jessica N.

AU - Kommoss, Stefan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort. Methods: ProMisE (POLE; MMR-D; p53 wt/NSMP; p53 abn) classification results from a cohort of 452 EC were available for analysis. L1CAM expression was studied by immunohistochemistry on whole slides. Correlations between clinicopathological data and survival were calculated. Results: Expression of L1CAM was most frequent in p53 abnormal tumours (80%). L1CAM status was predictive of worse outcome among tumours with no specific molecular profile (p53 wt/NSMP) (p < 0.0001). Among p53 wt/NSMP EC, L1CAM remained a significant prognosticator for disease-specific survival after multivariate analysis (p = 0.035). Conclusion: L1CAM status was able to significantly stratify risk among tumours of the large p53 wt/NSMP ProMisE subgroup of EC. Furthermore, our study confirms a highly significant correlation between mutation-type p53 immunostaining and abnormal L1CAM expression in EC.

AB - Background: The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort. Methods: ProMisE (POLE; MMR-D; p53 wt/NSMP; p53 abn) classification results from a cohort of 452 EC were available for analysis. L1CAM expression was studied by immunohistochemistry on whole slides. Correlations between clinicopathological data and survival were calculated. Results: Expression of L1CAM was most frequent in p53 abnormal tumours (80%). L1CAM status was predictive of worse outcome among tumours with no specific molecular profile (p53 wt/NSMP) (p < 0.0001). Among p53 wt/NSMP EC, L1CAM remained a significant prognosticator for disease-specific survival after multivariate analysis (p = 0.035). Conclusion: L1CAM status was able to significantly stratify risk among tumours of the large p53 wt/NSMP ProMisE subgroup of EC. Furthermore, our study confirms a highly significant correlation between mutation-type p53 immunostaining and abnormal L1CAM expression in EC.

UR - http://www.scopus.com/inward/record.url?scp=85050660683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050660683&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0187-6

DO - 10.1038/s41416-018-0187-6

M3 - Article

AN - SCOPUS:85050660683

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -